Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederir.allogene.com
Allogene Therapeutics News Releases
Get the latest updates from Allogene Therapeutics News Releases directly as they happen.
Follow now 95 followers
Latest posts
Last updated 2 days ago
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
2 days ago
SOUTH SAN FRANCISCO, Calif. , Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
15 days ago
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line...
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
23 days ago
Conference Call and Webcast Scheduled for August 13, 2025 at 2:00 p.m...
Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma
28 days ago
Lymphodepletion Regimen Selection Made in Conjunction with the ALPHA3 Data and Safety...
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
3 months ago
Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1...
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
3 months ago
SOUTH SAN FRANCISCO, Calif. , May 23, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel
3 months ago
SOUTH SAN FRANCISCO, Calif. , May 22, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
4 months ago
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line...
Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update
4 months ago
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m...
Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
4 months ago
SOUTH SAN FRANCISCO, Calif. , April 23, 2025 (GLOBE NEWSWIRE) -- Allogene...
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
5 months ago
Designations Follow Recent Investigational New Drug (IND) Application Clearance for the RESOLUTION...
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
6 months ago
Momentum Builds Across Programs with Key Data Milestones Expected in 2025 Cemacabtagene...